| Description | ATWLPPR Peptide TFA, a heptapeptide, acts as a selective neuropilin-1 inhibitor, inhibits VEGF 165 binding to NRP-1, used in the research of angiogenesis. ATWLPPR Peptide TFA has potential in reducing the early retinal damage caused by diabetes. Appearance:SolidIC50& Target:Neuropilin-1In Vitro:ATWLPPR Peptide TFA, a heptapeptide, acts as a selective neuropilin-1 inhibitor, inhibits VEGF 165 binding to NRP-1, used in the research of angiogenesis. ATWLPPR Peptide TFA has potential in reducing the early retinal damage caused by diabetes. Appearance:SolidIC50& Target:Neuropilin-1In Vitro:ATWLPPR Peptide TFA is a selective neuropilin-1 inhibitor, inhibits VEGF 165 binding to NRP-1 by 82% at 100 µM. MCE has not independently confirmed the accuracy of these methods. They are for reference only.In Vivo:ATWLPPR (400 µg/kg, s.c.) preserves vascular integrity and decreases the oxidative stress level, possibly reduces the early retinal damage caused by diabetes. ATWLPPR prevents the increase of inflammation-associated proteins (GFAP, VEGF and ICAM-1) iBiological Activity:ATWLPPR Peptide TFA, a heptapeptide, acts as a selective neuropilin-1 inhibitor, inhibits VEGF 165 binding to NRP-1, used in the research of angiogenesis. ATWLPPR Peptide TFA has potential in reducing the early retinal damage caused by diabetes... Read More | Amyloid β-Protein Fragment 25-35 (Aβ25-35) is derived from the amyloid-β protein.amyloid-β protein, which is mapped to human chromosome 21q21.Aβ25-35 lacks the N-terminal domain and the metal binding site and is majorly generated by proteolytic cleavage of Aβ(1−40Amyloid β-Protein Fragment 25-35 (Aβ25-35) is derived from the amyloid-β protein.amyloid-β protein, which is mapped to human chromosome 21q21.Aβ25-35 lacks the N-terminal domain and the metal binding site and is majorly generated by proteolytic cleavage of Aβ(1−40) peptides. It has a β-sheet and β-turn structure. Amino Acid Sequence Gly-Ser-Asn-Lys-Gly-Ala-Ile-Ile-Gly-Leu-MetFunctional domain of Aβ required for both neurotrophic and neurotoxic effects... Read More | Endothelin 3 (ET3) belongs to endothelin peptide family, which includes three members, ET-1, -2 and -3. These are 21-amino acid peptides, which are synthesized as precursors. They are converted to biologically active peptides, after being cleaved by proteases. There are two endothelin receptors Endothelin 3 (ET3) belongs to endothelin peptide family, which includes three members, ET-1, -2 and -3. These are 21-amino acid peptides, which are synthesized as precursors. They are converted to biologically active peptides, after being cleaved by proteases. There are two endothelin receptors called ETRA and ETRB, and ET3 binds to ETRB. It is localized to human intestine and colon.Application：Endothelin 3 has also been used as a ligand for endothelin receptor type B (EDNRB) in ex vivo enteric NCC (eNCC) migration assays. Endothelin 3 human, rat has been used for culturing neural tube explant culture, and the pharmacological study of endothelin receptors... Read More | Heme Oxygenase-1-IN-1 (Compound 2) is a heme oxygenase 1 ( HO-1 ) inhibitor with an IC 50 of 0.25 µMIC50& Target:IC 50 : 0.25 µM (HO-1) | Biochemical Test:SDS-PAGE (purity > 80%); Western blot with patient sample.Calculated Isoelectric Point:pH 5.68 |